Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells

Eggermont, Loek J.; Paulis, Leonie E. M.; Tel, Jurjen; Figdor, Carl G.

doi:10.1016/j.tibtech.2014.06.007

Cited by 193 publications

(149 citation statements)

References 87 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…5 However, both strategies have limitations, including a lack of responsive in some patients, 2 difficulty in treating solid tumors, 4 and off-target toxicities. 1,4,7,44 Therefore, it is of great clinical interest to develop alternative methods to potentiate cancer cell therapy. Accordingly, actin and integrin control by TAGLN2 may be used in combination with currently available cytotoxic T cell- and NK cell-mediated therapies.…”

Section: Discussionmentioning

confidence: 99%

Actin stabilizer TAGLN2 potentiates adoptive T cell therapy by boosting the inside-out costimulation via lymphocyte function-associated antigen-1

et al. 2018

View full text Add to dashboard Cite

Correct temporal and spatial control of actin dynamics is essential for the cytotoxic T cell effector function against tumor cells. However, little is known whether actin engineering in tumor-targeted T cells can enhance their antitumor responses, thereby potentiating the adoptive T cell therapy. Here, we report that TAGLN2, a 22-KDa actin-stabilizing protein which is physically associated with lymphocyte function-associated antigen-1 (LFA-1), potentiates the OTI TCR CD8+ T cells to kill the intercellular adhesion molecule-1 (ICAM-1)-positive/OVA-presenting E0771 cells, but not ICAM-1-negative OVA-B16F10 cells, suggesting an ‘inside-out’ activation of LFA-1, which causes more efficient immunological synapse formation between T cells and tumor cells. Notably, recombinant TAGLN2 fused with the protein transduction domain (TG2P) overcame the disadvantages of viral gene delivery, leading to a significant reduction in tumor growth in mice. TG2P also potentiated the CD19-targeted, chimeric antigen receptor (CAR)-modified T cells to kill Raji B-lymphoma cells. Our findings indicate that activating the TAGLN2–actin–LFA-1 axis is an effective strategy to potentiate the adoptive T-cell immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Actin stabilizer TAGLN2 potentiates adoptive T cell therapy by boosting the inside-out costimulation via lymphocyte function-associated antigen-1

et al. 2018

View full text Add to dashboard Cite

show abstract

“…These topics have been excellently reviewed by others (Caminschi et al, 2012;Eggermont et al, 2014;Mody et al, 2015) and will not be covered in this review.…”

Section: B Pharmacological Aspects Of Dendritic Cell-based Cancer Immentioning

confidence: 99%

Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy

Anguille¹,

Smits²,

Bryant³

et al. 2015

Pharmacol Rev

131

138

View full text Add to dashboard Cite

“…This information has been used to generate a new wave of therapeutic tools that program biological responses using rationally-designed biomaterials, including nanoparticles and hydrogels. Some examples of the programming potential of this new class of tools include more potent and sustained vaccine responses to pathogens [5–8], enhanced drug delivery and immunomodulation in the setting of cancer [9–18], amelioration of both acute and chronic inflammatory responses [19–22], and dampening autoimmunity and allergies through promotion of antigen-specific tolerance [23–25]. …”

Section: Introductionmentioning

confidence: 99%

Towards programming immune tolerance through geometric manipulation of phosphatidylserine

et al. 2015

View full text Add to dashboard Cite

The possibility of engineering the immune system in a targeted fashion using biomaterials such as nanoparticles has made considerable headway in recent years. However, little is known as to how modulating the spatial presentation of a ligand augments downstream immune responses. In this report we show that geometric manipulation of phosphatidylserine (PS) through fabrication on rod-shaped PLGA nanoparticles robustly dampens inflammatory responses from innate immune cells while promoting T regulatory cell abundance by impeding effector T cell expansion. This response depends on the geometry of PS presentation as both PS liposomes and 1 micron cylindrical PS-PLGA particles are less potent signal inducers than 80 × 320 nm rod-shaped PS-PLGA particles for an equivalent dose of PS. We show that this immune tolerizing effect can be co-opted for therapeutic benefit in a mouse model of multiple sclerosis and an assay of organ rejection using a mixed lymphocyte reaction with primary human immune cells. These data provide evidence that geometric manipulation of a ligand via biomaterials may enable more efficient and tunable programming of cellular signaling networks for therapeutic benefit in a variety of disease states, including autoimmunity and organ rejection, and thus should be an active area of further research.

show abstract

Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells

Cited by 193 publications

References 87 publications

Actin stabilizer TAGLN2 potentiates adoptive T cell therapy by boosting the inside-out costimulation via lymphocyte function-associated antigen-1

Actin stabilizer TAGLN2 potentiates adoptive T cell therapy by boosting the inside-out costimulation via lymphocyte function-associated antigen-1

Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy

Towards programming immune tolerance through geometric manipulation of phosphatidylserine

Contact Info

Product

Resources

About